Loading
Chief investigator of monarchE, the trial that added abemaciclib to adjuvant endocrine therapy for high-risk early breast cancer.
Stephen Johnston led monarchE, which showed two years of abemaciclib with endocrine therapy cuts recurrence in node-positive, high-risk HR-positive early breast cancer, the first adjuvant CDK4/6 inhibitor approval. His earlier work defined mechanisms of endocrine resistance and the fulvestrant dose used today. He continues to lead adjuvant and oral SERD trials from the Royal Marsden.
| Title | Journal | Year |
|---|---|---|
| Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE) | JCO | 2020 |
| Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial | Lancet Oncology | 2023 |
| monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer | Journal of Clinical Oncology | 2020 |
Shares CDK4/6, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer and the tags breast, trialist.
Shares The Institute of Cancer Research, The Royal Marsden, Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs) and the tag breast.
Shares the tags breast, trialist.
Shares CDK4/6, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer and the tags breast, trialist.
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tags breast, trialist.
Shares CDK4/6, Estrogen receptor (ERα), CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer and the tag breast.
Shares HR-positive / HER2-negative breast cancer and the tags breast, trialist.
Shares the tags breast, trialist.